-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q1 EPS $0.03
4:25PM ET 5/10/2022 MT Newswires...
Quotes Snapshot > CPIX
Cumberland Pharmaceuticals Inc CPIX:NASDAQ
Last Price$2.05NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/29/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.96 (1)
Ask (Size)$2.15 (5)
Day Low / HighN/A - N/A
Volume7.3 K
Read more news Recent News
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q1 Revenue $11.2M
4:24PM ET 5/10/2022 MT Newswires...
Cumberland Pharmaceuticals Swings to Loss in Q4 Amid Lower Revenue
5:05PM ET 3/08/2022 MT NewswiresCumberland Pharmaceuticals (CPIX) on Tuesday reported an adjusted loss of $0.13 per share in Q4, reversing from an adjusted profit of $0.01 a year earlier,...
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q4 Revenue $8.3M
4:10PM ET 3/08/2022 MT Newswires...
View all Commentary and Analysis
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2022 Results - Earnings Call Transcript
5:42PM ET 5/14/2022 Seeking AlphaCumberland Pharmaceuticals Inc. 2022 Q1 - Results - Earnings Call Presentation
10:06AM ET 5/13/2022 Seeking AlphaCumberland Pharmaceuticals Inc.'s (CPIX) CEO A.J. Kazimi on Q4 2021 Results - Earnings Call Transcript
11:08PM ET 3/08/2022 Seeking AlphaChecking In On Cumberland Pharmaceuticals
6:16AM ET 1/04/2022 Seeking AlphaCompany Profile
Business DescriptionCumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN. View company web site for more details
| Address | 2525 West End Avenue Nashville, Tennessee 37203 |
| Phone | +1.615.255.0068 |
| Number of Employees | 80 |
| Recent SEC Filing | 06/10/2022 4 |
| Chairman & Chief Executive Officer | A. J. Kazimi |
| Chief Financial & Accounting Officer | John M. Hamm |
| Chief Compliance Officer & Senior Vice President | James L. Herman |
| Executive Director-Organizational Development | Todd Anthony |
Company Highlights
| Price Open | $2.07 |
| Previous Close | $2.05 |
| 52 Week Range | $1.89 - 7.51 |
| Market Capitalization | $30.3 M |
| Shares Outstanding | 14.8 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.37 |
| Beta vs. S&P 500 | N/A |
| Revenue | $40.7 M |
| Net Profit Margin | -17.91% |
| Return on Equity | -14.69% |
Analyst Ratings as of 03/19/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |